VCEL (Vericel) Marketable Securities: $36.0 Mil (As of Mar. 2026)


VCEL Vericel Corp VCEL
81 GF Score
Price $46.98
GF Value $54.64
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Vericel Marketable Securities?

Vericel VCEL +4.05% 81 Marketable Securities is $36.0 Mil as of Mar. 2026. GuruFocus rates VCEL with a GF Score™ of 81/100 and a GF Value™ of $54.64 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Vericel's Marketable Securities for the quarter that ended in Mar. 2026 was $36.0 Mil.

Vericel's annual Marketable Securities increased from Dec. 2023 ($40.5 Mil) to Dec. 2024 ($41.7 Mil) but then declined from Dec. 2024 ($41.7 Mil) to Dec. 2025 ($37.4 Mil).

Vericel  (NAS:VCEL) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Vericel Marketable Securities Related Terms

Vericel Marketable Securities Historical Data

* Premium members only.

The historical data trend for Vericel's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vericel Marketable Securities Chart

Vericel Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.07 68.47 40.47 41.69 37.41

Vericel Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.41 36.35 34.98 37.41 36.05
VCEL
81GF Score
Vericel Corp VCEL
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vericel Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $36.0 Mil mean?
Vericel (VCEL) has a Marketable Securities of $36.0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vericel and its competitors.
Is Vericel's Marketable Securities too high?
Vericel's current Marketable Securities is $36.0 Mil. Overall, Vericel has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's Marketable Securities compare to NRIX and MLYS?
Vericel's Marketable Securities of $36.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vericel and its competitors. Vericel's current Marketable Securities is $36.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $54.64, compared to a current price of $46.98 — trading 14% below its estimated fair value. The current Marketable Securities is $36.0 Mil. Vericel's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Vericel (VCEL), the current Marketable Securities is $36.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vericel (VCEL) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of $46.98 is trading 14% below its estimated GF Value™ of $54.64. GuruFocus considers Vericel to be Modestly Undervalued.

Key valuation signals for VCEL:

  • Marketable Securities: $36.0 Mil
  • GF Value™: $54.64 vs. price of $46.98 (14% below fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges ATQP:Germany
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
81GF Score

Get the complete analysis for VCEL

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.98
Price
$54.64
GF Value